PBRER (Periodic Benefit-Risk Evaluation Report)
Last reviewedA Periodic Benefit-Risk Evaluation Report (PBRER) is the post-approval periodic report in which a marketing authorisation holder evaluates new safety information in the context of a product's cumulative benefit-risk profile. It is defined in ICH E2C(R2) and replaced the earlier PSUR format.
Key facts
| Guideline | ICH E2C(R2) |
|---|---|
| Applies to | Approved medicines |
| Frequency | Every 6 or 12 months, or less often, depending on the product and the region |
| Due | Within 70 calendar days of the data lock point for reports covering 6 or 12 months; within 90 calendar days for intervals longer than 12 months |
| Reference information | The latest Company Core Data Sheet (CCDS) is a practical option; otherwise another document such as the USPI or EU SmPC |
| EU name | PSUR |
What a PBRER contains
The report covers worldwide marketing status, estimated exposure, summary tabulations, signals evaluated during the interval, an evaluation of risks and of benefits, and an integrated benefit-risk analysis for the approved indications.
Sources
Read more
Part of our guide to Pharmacovigilance Aggregate Reports: DSUR, PBRER, PSUR and PADER

